Compare Incyte Corporation (INCY) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wheaton Precious Metals Corp — how do they compare? Incyte Corporation trades at $117.61 (market cap $23.11B), while Wheaton Precious Metals Corp trades at $107.25 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is far larger — about 2× Incyte Corporation's market cap, and Wheaton Precious Metals Corp pays a 0.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WPM | |
|---|---|---|
Market Cap | $23.11B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $165.72 |
52-Week Low | $67.38 | $91.00 |
Enterprise Value | $19.13B | $44.39B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Wheaton Precious Metals (WPM) trades at $103.81, down 0.36% today, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.24 estimate. Revenue surged to $2.31 billion in 2025, driving a net income margin of 63.58%. Operating cash flow reached a record $1.90 billion, supporting a positive net cash flow of $335.43 million. Analyst consensus remains strongly bullish with an 80% buy rating and a $161.75 price target, indicating significant upside potential.
WPM presents a compelling investment case based on robust fundamentals and strong analyst support, though technical indicators suggest near-term caution. Key opportunities include sustained earnings growth, high profit margins, and a solid cash flow outlook. Risks involve exposure to precious metal price volatility, geopolitical tensions impacting mining operations, and potential valuation compression if silver prices remain subdued. The stock's current price offers an attractive entry point relative to analyst targets, but investors should monitor commodity market trends and quarterly performance closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
